CRISPR Therapeutics AG — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CRISPR Therapeutics AG filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $77.02M | Feb 12, 2020 |
| FY2019 | Sep 30, 2019 | $211.93M | Feb 12, 2020 |
| FY2019 | Jun 30, 2019 | $318.0K | Feb 12, 2020 |
| FY2019 | Mar 31, 2019 | $328.0K | Feb 12, 2020 |
| FY2019 | Dec 31, 2018 | $115.0K | Feb 12, 2020 |
| FY2019 | Sep 30, 2018 | $563.0K | Feb 12, 2020 |
| FY2019 | Jun 30, 2018 | $1.09M | Feb 12, 2020 |
| FY2019 | Mar 31, 2018 | $1.36M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | $32.33M | Feb 25, 2019 |
| FY2018 | Sep 30, 2017 | $2.39M | Feb 25, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.51M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $37.31M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $371.21M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.20M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $914.96M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $370.0K | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | $148.0K | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | $44.0K | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | $157.0K | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $77.02M | Feb 16, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($581.60M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($366.25M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($153.61M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($650.18M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $377.66M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | ($107.04M) | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | ($92.44M) | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | ($79.66M) | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | ($69.73M) | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $30.54M | Feb 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($664.57M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($466.57M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($222.54M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($673.16M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $373.53M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | ($107.76M) | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | ($92.40M) | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | ($80.69M) | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | ($73.59M) | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $10.98M | Feb 16, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $284.81M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $310.24M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $387.33M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $461.65M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $340.57M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $221.38M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $179.36M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $113.77M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $69.80M | Feb 12, 2020 |
| FY2018 | Dec 31, 2016 | $42.24M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($345.01M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($142.77M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($260.38M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | ($495.74M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $538.97M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | ($238.37M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $56.68M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | ($96.24M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | ($70.09M) | Feb 12, 2020 |
| FY2018 | Dec 31, 2016 | ($52.86M) | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $914.0K | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.90M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $9.47M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $37.19M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $81.71M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $18.36M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $6.68M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $2.77M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $7.81M | Feb 12, 2020 |
| FY2018 | Dec 31, 2016 | $3.02M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.27B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.24B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $2.23B | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $2.24B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $2.75B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.83B | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.07B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $489.02M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | $271.35M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $344.96M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $343.43M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $309.95M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $346.77M | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | $367.58M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $352.42M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $163.73M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $127.33M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $96.82M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | $83.51M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $112.12M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.92B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.93B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.88B | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | $1.88B | Feb 12, 2026 |
| FY2024 | Dec 31, 2021 | $2.40B | Feb 11, 2025 |
| FY2023 | Dec 31, 2020 | $1.66B | Feb 21, 2024 |
| FY2022 | Dec 31, 2019 | $939.43M | Feb 21, 2023 |
| FY2021 | Dec 31, 2018 | $392.20M | Feb 15, 2022 |
| FY2020 | Dec 31, 2017 | $187.83M | Feb 16, 2021 |
| FY2019 | Dec 31, 2016 | $232.85M | Feb 12, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.95B) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($1.37B) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | ($999.70M) | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | ($846.09M) | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | ($195.92M) | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | ($573.58M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | ($224.71M) | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | ($291.57M) | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | ($125.44M) | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | ($57.08M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $347.56M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $298.26M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $389.48M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $211.89M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $923.03M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $1.17B | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $943.77M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $456.65M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $239.76M | Feb 12, 2020 |
| FY2018 | Dec 31, 2016 | $315.52M | Feb 25, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (8) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | (1) | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | (1) | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | (1) | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | (8) | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 4 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | (1) | Feb 16, 2021 |
| FY2020 | Sep 30, 2020 | (1) | Feb 16, 2021 |
| FY2020 | Jun 30, 2020 | (1) | Feb 16, 2021 |
| FY2020 | Mar 31, 2020 | (1) | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 95.89M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 85.74M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 80.04M | Feb 11, 2025 |
| FY2023 | Dec 31, 2022 | 78.51M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | 76.99M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | 73.91M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | 60.78M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | 51.85M | Feb 12, 2020 |
| FY2018 | Dec 31, 2017 | 40.59M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | 39.72M | Mar 8, 2018 |